Glaxo Smith Kline

GSK

Abstract

Pharmaceuticals produce varying products to capitalize on the expenditure during the research and development process. This offers an explanation to the constant changes in the industry, whereby, medication now allow for changes in the delivery process. Medication now offers an extended release formula as well as the original version whereby the effect of the medication would take effect within twenty minutes after consumption. All these changes put a constant demand on the chemist and with many suppliers of the Oligopoly runs rampant with ingenuity.

Business Proposal for Glaxo Smith Kline (GSK)

The time line of Glaxo Smith Kline is one of many changes when in its inception in 1907 the manufacturer produced fruits and vegetables and salts in 1938 a merger took place and the product line increased to tooth paste, malted milk and energy drinks. It was not until 1960 when the manufacturing company started producing pharmaceuticals with its flagship being cold relief medication and in 2001 the name Glaxo Smith Kline emerged through mergers and product line increases. This business proposal looks at how an active research and development process can be a variable cost and how to manage this cost while increasing revenue. The drug investigated is called Paxil and the compounded name is “paroxetine hydrochloride” (GSK.com) and its main purpose is to correct symptoms of depression by adjusting the chemical reactions in the brain. This mood corrective drug requires constant use and because the depression is sporadic by nature the research and development department has incorporated a controlled release feature that is triggered by a chemical imbalance. This feature allows for greater consumption because it reduces the need for a regular doctor (MD) visit for evaluation but on the other hand increases the need for a psychologist to evaluate.

GlaxoSmithKline: Paxil

Paroxetine hydrochloride is the compound for the drug brand name Paxil and it is medication...